CARL ZEISS MEDITEC AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.5 EUR | -3.79% |
|
-24.40% | -34.20% |
| 06-19 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades |  |
| 06-18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The firm trades with high earnings multiples: 27.73 times its 2024 earnings per share.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -34.20% | 6.16B | - | ||
| +6.37% | 216B | B | ||
| +10.21% | 189B | B- | ||
| +28.22% | 153B | B- | ||
| +34.42% | 114B | A- | ||
| +0.80% | 63.2B | A- | ||
| +19.21% | 54.78B | B+ | ||
| +0.13% | 48.47B | B+ | ||
| -4.16% | 38.88B | A | ||
| +2.39% | 36.14B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AFX Stock
- AFXA Stock
- Ratings Carl Zeiss Meditec AG
